The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line

被引:9
|
作者
Zduniak, Krzysztof [1 ]
Gdesz-Birula, Katarzyna [1 ]
Wozniak, Marta [1 ]
Dus-Szachniewicz, Kamila [1 ]
Ziolkowski, Piotr [1 ]
机构
[1] Wroclaw Med Univ, Dept Pathol, Marcinkowskiego 1, PL-50368 Wroclaw, Poland
来源
MOLECULES | 2020年 / 25卷 / 21期
关键词
photodynamic therapy; thalidomide; breast carcinoma; in vitro; VEGF; COMBINATION THERAPY; GROWTH;
D O I
10.3390/molecules25215184
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Photodynamic therapy (PDT) is a low-invasive method of treatment of various diseases, mainly neoplastic conditions. PDT has been experimentally combined with multiple treatment methods. In this study, we tested a combination of 5-aminolevulinic acid (5-ALA) mediated PDT with thalidomide (TMD), which is a drug presently used in the treatment of plasma cell myeloma. TMD and PDT share similar modes of action in neoplastic conditions. Using 4T1 murine breast carcinoma and 2H11 murine endothelial cells lines as an experimental tumor model, we tested 5-ALA-PDT and TMD combination in terms of cytotoxicity, apoptosis, Vascular Endothelial Growth Factor (VEGF) expression, and, in 2H11 cells, migration capabilities by wound healing assay. We have found an enhancement of cytotoxicity in 4T1 cells, whereas, in normal 2H11 cells, this effect was not statistically significant. The addition of TMD decreased the production of VEGF after PDT in 2H11 cell line. Our results reveal enhanced effectiveness of 5-ALA-PDT with TMD treatment compared to 5-ALA-PDT or TMD treatment alone. The addition of TMD may be a promising proceeding of the anti-tumor effect of PDT by decreasing the VEGF concentration in the culture medium. Further studies, including testing on different cell lines, are needed to confirm this assumption.
引用
收藏
页数:10
相关论文
共 9 条
  • [1] Antitumor effect of combined Dkk-3 and 5-ALA mediated photodynamic therapy in breast cancer cell's colony
    Mohammadpour, Henan
    Fekrazad, Reza
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2016, 14 : 200 - 203
  • [2] Optimizing the administrated light dose during 5-ALA-mediated photodynamic therapy: Murine 4T1 breast cancer model
    Amiri, Hossein
    Mokhtari-Dizaji, Manijhe
    Mozdarani, Hossein
    PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2024, 40 (01)
  • [3] 5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death
    Sun, Zhuoran
    Zhao, Mingyi
    Wang, Weibi
    Hong, Lanhui
    Wu, Zhongguang
    Luo, Guang
    Lu, Siyao
    Tang, Yueyue
    Li, Jiehan
    Wang, Jiangang
    Zhang, Yingjie
    Zhang, Lingling
    CANCER LETTERS, 2023, 554
  • [4] Gold nanocages co-assembled with Spinacia oleracea extract combined photothermal/photodynamic therapy in 4T1 breast cancer cell line
    Dehariya, Dheeraj
    Tarafdar, Anindita
    Pebam, Monika
    Sankaranarayanan, Sri Amruthaa
    Khatun, Sajmina
    Rengan, Aravind Kumar
    BIOMEDICAL MATERIALS, 2025, 20 (02)
  • [5] Study of the Efficacy of 5 ALA-Mediated Photodynamic Therapy on Human Larynx Squamous Cell Carcinoma (Hep2c) Cell Line
    Khursid, A.
    Atif, M.
    Firdous, S.
    Zaidi, S. S. Z.
    Salman, R.
    Ikram, M.
    LASER PHYSICS, 2010, 20 (07) : 1673 - 1678
  • [6] The effects of Ce6-mediated sono-photodynamic therapy on cell migration, apoptosis and autophagy in mouse mammary 4T1 cell line
    Li, Qing
    Liu, Quanhong
    Wang, Pan
    Feng, Xiaolan
    Wang, Haiping
    Wang, Xiaobing
    ULTRASONICS, 2014, 54 (04) : 981 - 989
  • [7] Redox Proteomics of 4T1 Breast Cancer Cell After Treatment with MnTE-2-PyP5+/Ascorbate System
    Tovmasyan, Artak
    Go, Young-Mi
    Jones, Dean
    Spasojevic, Ivan
    Batinic-Haberle, Ines
    FREE RADICAL BIOLOGY AND MEDICINE, 2016, 100 : S112 - S113
  • [8] Molecular docking simulation and anticancer assessment on human breast carcinoma cell line using novel bis(1,4-dihydropyrano[2,3-c] pyrazole-5-carbonitrile) and bis(1,4-dihydropyrazolo[4′,3′: 5,6] pyrano [2,3-b] pyridine-6-carbonitrile) derivatives
    Salama, Soad K.
    Mohamed, Magda F.
    Darweesh, Ahmed F.
    Elwahy, Ahmed H. M.
    Abdelhamid, Ismail A.
    BIOORGANIC CHEMISTRY, 2017, 71 : 19 - 29
  • [9] Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336)
    Bruzek, LM
    Poynter, JN
    Kaufmann, SH
    Adjei, AA
    MOLECULAR PHARMACOLOGY, 2005, 68 (02) : 477 - 486